BIT
PGNX

BlackRock Institutional Trust’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

BlackRock Institutional Trust’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$17M Buy
1,963,062
+22,509
+1% +$166K ﹤0.01% 2081
2016
Q3 		$12.3M Buy
1,940,553
+163,595
+9% +$989K ﹤0.01% 2216
2016
Q2 		$7.5M Sell
1,776,958
-17,317
-1% -$83.6K ﹤0.01% 2465
2016
Q1 		$7.82M Buy
1,794,275
+7,853
+0.4% +$35K ﹤0.01% 2427
2015
Q4 		$11M Sell
1,786,422
-37,167
-2% -$244K ﹤0.01% 2262
2015
Q3 		$10.4M Sell
1,823,589
-209,436
-10% -$1.61M ﹤0.01% 2273
2015
Q2 		$15.2M Sell
2,033,025
-47,517
-2% -$287K ﹤0.01% 2108
2015
Q1 		$12.4M Buy
2,080,542
+7,881
+0.4% +$49.6K ﹤0.01% 2251
2014
Q4 		$15.7M Sell
2,072,661
-265,000
-11% -$1.59M ﹤0.01% 2066
2014
Q3 		$12.1M Sell
2,337,661
-62,487
-3% -$311K ﹤0.01% 2204
2014
Q2 		$10.3M Buy
2,400,148
+34,784
+1% +$133K ﹤0.01% 2416
2014
Q1 		$9.67M Buy
2,365,364
+444,873
+23% +$2.28M ﹤0.01% 2444
2013
Q4 		$10.2M Buy
1,920,491
+114,923
+6% +$506K ﹤0.01% 2406
2013
Q3 		$9.06M Buy
1,805,568
+312,557
+21% +$1.7M ﹤0.01% 2422
2013
Q2 		$6.66M Buy
+1,493,011
New +$6.7M ﹤0.01% 2552

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $637M AUM 39.08% 1-Year Est. Return

BlackRock Institutional Trust's PGNX Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Progenics Pharmaceuticals Inc (PGNX) stake by 1.2% in Q4 2016, buying an estimated $166K and bringing the position to 1,963,062 shares worth $17M. The position accounts for ﹤0.01% of the portfolio, ranked #2081.

BlackRock Institutional Trust first reported a position in PGNX in Q2 2013 and has held it in 15 quarters since. 126 funds tracked by Wall St. Rank hold PGNX as of Q4 2016.

  • BlackRock Institutional Trust held 1,963,062 shares of Progenics Pharmaceuticals Inc worth $17M as of Q4 2016.
  • BlackRock Institutional Trust bought 22,509 Progenics Pharmaceuticals Inc shares in Q4 2016, an estimated $166K.
  • Progenics Pharmaceuticals Inc made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2081 holding.
  • BlackRock Institutional Trust first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and has held it in 15 quarters since.
  • 126 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.